Quarter | Prior | Estimate | Actual | Surprise | |
---|---|---|---|---|---|
Q4 2019 Pre-Market | EPS: REV: | 0.78 141.605M | |||
Q3 2019 Pre-Market | EPS: REV: | 0.81 141.989M | |||
Q2 2019 Pre-Market | EPS: REV: | 0.86 143.405M | |||
Q1 2019 After-Hours | EPS: REV: | 0.78 142.115M | |||
Q4 2018 Pre-Market | EPS: REV: | 0.67 139.915M | 0.8 142.77M | 0.78 141.605M | -2.5% -0.82% |
Q3 2018 Pre-Market | EPS: REV: | 0.68 137.336M | 0.78 141.54M | 0.81 141.989M | 3.85% 0.32% |
Q2 2018 Pre-Market | EPS: REV: | 0.67 129.255M | 0.8 143.91M | 0.86 143.405M | 7.5% -0.35% |
Q1 2018 After-Hours | EPS: REV: | 0.57 111.592M | 0.73 137.76M | 0.78 142.115M | 6.85% 3.16% |
Q4 2017 Pre-Market | EPS: REV: | 0.61 109.192M | 0.68 138.45M | 0.67 139.915M | -1.47% 1.06% |
Q3 2017 Pre-Market | EPS: REV: | 0.61 108.415M | 0.66 139.33M | 0.68 137.336M | 3.03% -1.43% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- 'We See Room For Further Outperformance': CyberArk Analysts Bullish After Q4 Earnings Beat
- KeyBanc: Diebold's New CEO Executing Well, But Long-Term Growth Remains A Concern
- Dana Inc. Beats Q4 And Full-Year 2018 Expectations
- Analysts Aren't Cutting CBS Despite Earnings Miss
- The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings